cabozantinib
≥99.5%
- Product Code: 53906
CAS:
849217-68-1
| Molecular Weight: | 501.52 g./mol | Molecular Formula: | C₂₈H₂₄FN₃O₅ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD20926324 | |
| Melting Point: | Boiling Point: | 758.075°C | |
| Density: | 1.397 g/mL | Storage Condition: | room temperature, dry |
Product Description:
Cabozantinib is primarily used in the treatment of certain types of cancer. It is effective in managing advanced renal cell carcinoma (RCC), a type of kidney cancer, particularly in patients who have previously received anti-angiogenic therapy. The drug is also utilized for treating hepatocellular carcinoma (HCC), a common form of liver cancer, in patients who have been previously treated with sorafenib. Additionally, cabozantinib has shown promise in treating medullary thyroid cancer (MTC) in patients with progressive, metastatic disease. Its mechanism of action involves inhibiting multiple tyrosine kinases, which play a role in tumor growth, angiogenesis, and metastasis, making it a valuable option in targeted cancer therapy.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to Off-White Solid |
| PURITY | 99.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.100 | 10-20 days | ฿3,600.00 |
+
-
|
| 0.250 | 10-20 days | ฿7,060.00 |
+
-
|
| 1.000 | 10-20 days | ฿15,000.00 |
+
-
|
| 5.000 | 10-20 days | ฿35,500.00 |
+
-
|
cabozantinib
Cabozantinib is primarily used in the treatment of certain types of cancer. It is effective in managing advanced renal cell carcinoma (RCC), a type of kidney cancer, particularly in patients who have previously received anti-angiogenic therapy. The drug is also utilized for treating hepatocellular carcinoma (HCC), a common form of liver cancer, in patients who have been previously treated with sorafenib. Additionally, cabozantinib has shown promise in treating medullary thyroid cancer (MTC) in patients with progressive, metastatic disease. Its mechanism of action involves inhibiting multiple tyrosine kinases, which play a role in tumor growth, angiogenesis, and metastasis, making it a valuable option in targeted cancer therapy.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :